Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice

Journal of Diabetes

Volumn 5, Issue 2, 2013, Pages 163-171

  Patel, Vishal ^a   Joharapurkar, Amit ^a   Gandhi, Tejal ^b   Patel, Kirti ^b   Dhanesha, Nirav ^a   Kshirsagar, Samadhan ^a   Dhote, Vipin ^a   Detroja, Jaysukh ^a   Bahekar, Rajesh ^a   Jain, Mukul ^a  

^a ZYDUS RESEARCH CENTRE   (India)

^b ANAND PHARMACY COLLEGE   (India)

Author keywords

Diabetes; Exendin 4; Obesity; Omeprazole

Indexed keywords

EXENDIN 4; GASTRIN; GHRELIN; GLUCAGON; GLUCOKINASE; HEMOGLOBIN A1C; INSULIN; LEPTIN; OMEPRAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; FOOD INTAKE; GASTRIN BLOOD LEVEL; GLYCEMIC CONTROL; MALE; MOUSE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS; PRIORITY JOURNAL; TREATMENT DURATION; WEIGHT CONTROL; WEIGHT REDUCTION;

ANIMALS; ANTI-OBESITY AGENTS; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GASTRINS; GLUCAGON; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LEPTIN; MALE; MICE; MICE, INBRED STRAINS; MICE, OBESE; OBESITY; OMEPRAZOLE; PEPTIDES; VENOMS;

EID: 84877029732     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/j.1753-0407.2012.00227.x     Document Type: Article

References (37)

1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001; 414: 782-7.
2. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med. 1998; 15: 297-303.
3. James WP. The epidemiology of obesity: The size of the problem. J Intern Med. 2008; 263: 336-52.
4. Tahrani AA, Bailey CJ, Del Prato S, Barnett AH. Management of type 2 diabetes: New and future developments in treatment. Lancet. 2011; 378: 182-97.
5. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): A potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004; 117: 77-88.
6. Gentilella R, Bianchi C, Rossi A et al.Exenatide: A review from pharmacology to clinical practice. Diabetes Obes Metab. 2009; 11: 544-56.
7. Rooman I, Lardon J, Bouwens L. Gastrin stimulates beta-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue. Diabetes. 2002; 51: 686-90.
8. Wang TC, Bonner-Weir S, Oates PS et al.Pancreatic gastrin stimulates islet differentiation of transforming growth factor alpha-induced ductular precursor cells. J Clin Invest. 1993; 92: 1349-56.
9. Yoshihisa U, Susumu I, Yasuyuki M et al.Effect of serum gastrin concentration on insulin resistance. Digestion Absorption. 2006; 28: 42-5.
10. Creutzfeldt W. The consequences of hypergastrinemia. Yale J Biol Med. 1994; 67: 709-23.
11. Suarez-Pinzon WL, Power RF, Yan Y, Wasserfall C, Atkinson M, Rabinovitch A. Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes. 2008; 57: 3281-8.
12. Ligumsky M, Lysy J, Siguencia G, Friedlander Y. Effect of long-term, continuous versus alternate-day omeprazole therapy on serum gastrin in patients treated for reflux esophagitis. J Clin Gastroenterol. 2001; 33: 32-5.
13. Suarez-Pinzon WL, Cembrowski GS, Rabinovitch A. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice. Diabetologia. 2009; 52: 1680-2.
14. Ogawa N, List JF, Habener JF, Maki T. Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. Diabetes. 2004; 53: 1700-5.
15. Yasuda N, Inoue T, Nagakura T et al.Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats. J Pharmacol Exp Ther. 2004; 310: 614-9.
16. Ohta R, Shigemura N, Sasamoto K, Koyano K, Ninomiyaa Y. Conditioned taste aversion learning in leptin-receptor-deficient db/db mice. Neurobiol Learn Mem. 2003; 80: 105-12.
17. 2+, oxygen consumption, and insulin secretion in glucose-stimulated rat pancreatic islets. J Biol Chem. 1991; 266: 9314-9.
18. Davidson AL, Arion WJ. Factors underlying significant underestimations of glucokinase activity in crude liver extracts: Physiological implications of higher cellular activity. Arch Biochem Biophys. 1987; 253: 156-67.
19. Young AA, Gedulin BR, Bhavsar S et al.Glucose-lowering and insulin-sensitizing actions of exendin-4: Studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes. 1999; 48: 1026-34.
20. Friedman JM. The functions of leptin in nutrition, weight and physiology. Nutr Rev. 2002; 60(Suppl.): S1-14.
21. Knight ZA, Hannan KS, Greenberg ML, Friedman JM. Hyperleptinemia is required for the development of leptin resistance. PLoS ONE. 2010; 6: e11376.
22. Williams DL, Baskin DG, Schwartz MW. Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. Diabetes. 2006; 55: 3387-93.
23. Bojanowska E, Nowak A. Interactions between leptin and exendin-4, a glucagon-like peptide-1 agonist, in the regulation of food intake in the rat. J Physiol Pharmacol. 2007; 58: 349-60.
24. Al-Barazanji KA, Arch JR, Buckingham RE, Tadayyon M. Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa/fa) Zucker rats. Obes Res. 2000; 8: 317-23.
25. Cui GL, Syversen U, Zhao CM, Chen D, Waldum HL. Long-term omeprazole treatment suppresses body weight gain and bone mineralization in young male rats. Scand J Gastroenterol. 2001; 36: 1011-5.
26. Eissele R, Bothe-Sandfort E, Göke B, Eng J, Arnold R, Koop H. Rat gastric somatostatin and gastrin release: Interactions of exendin-4 and truncated glucagon-like peptide-1 (GLP-1) amide. Life Sci. 1994; 55: 629-34.
27. Wren AM, Small CJ, Ward HL et al.The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology. 2000; 141: 4325-8.
28. Ishii S, Kamegai J, Tamura H, Shimizu T, Sugihara H, Oikawa S. Role of ghrelin in streptozotocin-induced diabetic hyperphagia. Endocrinology. 2002; 143: 4934-7.
29. Pérez-Tilve D, González-Matías L, Alvarez-Crespo M et al.Exendin-4 potently decreases ghrelin levels in fasting rats. Diabetes. 2007; 56: 143-51.
30. DelParigi A, Tschop M, Heiman ML et al.High circulating ghrelin: a potential cause for hyperphagia and obesity in Prader-Willi syndrome. J Clin Endocrinol Metab. 2002; 87: 5461-4.
31. Kanoski SE, Rupprecht LE, Fortin SM, De Jonghe BC, Hayes MR. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. Neuropharmacology. 2012; 62: 1916-27.
32. Liang NC, Bello NT, Moran TH. Additive feeding inhibitory and aversive effects of naltrexone and exendin-4 combinations. Intl J Obes. 2012. doi:10.1038/ijo.2012.16 (Epub ahead of print).
33. Bouckenooghe T, Vandewalle B, Lukowiak B et al.Modulation of specific beta cell gene (re)expression during in vitro expansion of human pancreatic islet cells. Cell Transplant. 2003; 12: 799-807.
34. Nakagawa T, Tsuchida A, Itakura Y et al.Brain-derived neurotrophic factor regulates glucose metabolism by modulating energy balance in diabetic mice. Diabetes. 2000; 49: 436-44.
35. Murao K, Li J, Imachi H et al.Exendin-4 regulates glucokinase expression by CaMKK/CaMKIV pathway in pancreatic beta-cell line. Diabetes Obes Metab. 2009; 11: 939-46.
36. Ohkubo Y, Kishikawa H, Araki E et al.Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with noninsulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract. 1995; 28: 103-17.
37. Crouch MA, Mefford IN, Wade EU. Proton pump inhibitor therapy associated with lower glycosylated hemoglobin levels in type 2 diabetes. J Am Board Fam Med. 2012; 25: 50-4.